Skip to main content

Advertisement

SpringerLink
Log in

On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics

  • Original Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

Abstract

Introduction and hypothesis

We aimed to compare on-demand and continuous use of fesoterodine 4 mg concerning efficacy and adverse effects.

Methods

A total of 100 patients who were diagnosed with non-neurogenic overactive bladder (OAB) syndrome were included in the study. All patients were evaluated with MMSE, ICIQ-SF, SEAPI quality of health and OAB-V8 questionnaires, at the beginning, 1st month and 4th month. Fesoterodine 4 mg was started for treatment. At the end of the 1st month, patients who obtained benefit from the treatment were 1:1 randomized into two groups. In group 1, fesoterodine 4 mg was given 1 × 1 in a standard manner whereas in group 2 patients took the pills on demand. Both groups were evaluated for efficacy and adverse events at 4 months.

Results

Final analyses included 69 patients. At 4-month follow-up, OAB-V8 scores were significantly improved compared to 1 month in both groups. Again at h months, no difference was detected between the two groups for MMSE, ICIQ-SF and SEAPI scores. In continuous usage group, 4th month MMSE scores were significantly lower than 1st month scores. At 4 months, dry mouth and constipation were lower in the on-demand group compared to continuous usage group.

Conclusions

Compared to standard continuous usage, on-demand usage of fesoterodine showed similar efficacy with fewer adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2

Similar content being viewed by others

References

  1. Haylen BT, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4.

    Article  Google Scholar 

  2. Kalder M, Pantazis K, Dinas K, et al. Discontinuation of treatment using anticholinergic medications in patients with urinary incontinence. Obstet Gynecol. 2014;124:794–800. https://doi.org/10.1097/AOG.0000000000000468.

    Article  CAS  PubMed  Google Scholar 

  3. Shamliyan T, Wyman J, Kane RL. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr. Report No.: 11(12)-EHC074-EF.

  4. Novara G, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol. 2008;54:740.

    Article  CAS  Google Scholar 

  5. EAU. Guidelines on non-neurogenic female LUTS. 2021. Accessed at 07/03/2022.

  6. Güngen C, Ertan C, Eker E, et al. Standardize mini mental test’ in Türk toplumunda hafif demans tanısında geçerlik ve güvenilirliği. Türk Psikiyatri Dergisi. 2002;13:273–81.

    PubMed  Google Scholar 

  7. Cetinel B, Ozkan B, Can G. ICIQ-SF Türkçe versiyonu validasyon (geçerlilik) çalışması. Türk Üroloji Dergisi. 2004;30:332–8.

    Google Scholar 

  8. Tarcan T, Akbal C, Tinay I, et al. "SEAPI QMM sorgulama formununTürkçe validasyonu ve TVT başarısı değerlendirmesinde kullanılması," 1. Antalya: Pelvik Taban Sağlığı ve İşeme Bozuklukları Kongresi; 2007.

    Google Scholar 

  9. Tarcan T, Mangir N, Ozgur MO, et al. OAB V-8 Aşırı aktif mesane sorgulama formu validasyon çalışması. Üroloji Bülteni. 2012;21:113–6.

    Google Scholar 

  10. Alla MF, Mahmoud AM, Sayed Youssef AE. Safety and efficacy of intermittent versus continuous anticholinergic medication in management of overactive bladder in adult. Egyptian J Hospital Med. 2018;70:223–7.

    Article  Google Scholar 

  11. Oelke M, Becher K, Castro-Diaz D, et al. Appropriateness of oral drugs for long-term treatment of lower urinary tract symptoms in older persons: results of a systematic literature review and international consensus validation process (LUTS-FORTA 2014). Age Ageing. 2015;44:745–55.

    Article  Google Scholar 

  12. Malhotra B, Darsey E, Crownover P, Fang J, Glue P. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. Br J Clin Pharmacol. 2011;72(2):226–34. https://doi.org/10.1111/j.1365-2125.2011.03948.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health. 2008;11:726–32. https://doi.org/10.1111/j.1524-4733.2007.00295.x.

    Article  PubMed  Google Scholar 

  14. Paquette A, Gou P, Tannenbaum C. Systematic review and meta-analysis: Do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J Am Geriatr Soc. 2011;59:1332–9.

    Article  Google Scholar 

  15. Przydacz M, Campeau L, Walter JE, Corcos J. How long do we have to treat overactive bladder syndrome (OAB)? A questionnaire survey of Canadian urologists and gynecologists. Can Urol Assoc J. 2018;12(9):E378–83. https://doi.org/10.5489/cuaj.5032.

    Article  PubMed Central  Google Scholar 

  16. Choo MS, Song C, Kim JH, et al. Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial. J Urol. 2005;174:201–4. https://doi.org/10.1097/01.ju.0000161597.30736.21 Erratum in: J Urol. 2005 Oct;174(4 Pt 1):1505.

    Article  CAS  PubMed  Google Scholar 

  17. Lee YS, Choo MS, Lee JY, et al. Symptom change after discontinuation of successful antimuscarinic treatment in patients with overactive bladder symptoms: a randomised, multicentre trial. Int J Clin Pract. 2011;65:997–1004. https://doi.org/10.1111/j.1742-1241.2011.02728.x.

    Article  PubMed  Google Scholar 

  18. Khullar V, Cardozo L, Kelleher CJ, et al. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder. BJU Int. 2013;112:820–9. https://doi.org/10.1111/bju.12006 Epub 2013 Mar 7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Izmir Bozyaka Training and Research Hospital, Department of Urology, University of Health Sciences, Izmir, Turkey

    Ibrahim Halil Bozkurt, Serdar Celik, Arda Yesilova & Tansu Degirmenci

  2. Department of Urology, Izmir Tinaztepe Galen Hospital, Izmir, Turkey

    Ertugrul Sefik

  3. Faculty of Medicine, Department of Urology, Mustafa Kemal University, Hatay, Turkey

    Omer Koras

Authors
  1. Ibrahim Halil Bozkurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ertugrul Sefik
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Serdar Celik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arda Yesilova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Omer Koras
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tansu Degirmenci
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

IH Bozkurt: Protocol/project development, Manuscript writing, Management

E Sefik: Data collection, Manuscript writing

S Celik: Data collection, Data analysis

A Yesilova: Data collection

O Koras: Data collection, Editing

T Degirmenci: Management, Editing

Corresponding author

Correspondence to Ibrahim Halil Bozkurt.

Ethics declarations

Ethical approval

The study protocol was approved by the local ethics committee (approval number: 28.08.2019:03).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Conflicts of interest

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bozkurt, I.H., Sefik, E., Celik, S. et al. On-demand use of fesoterodine: a new paradigm for extended release antimuscarinics. Int Urogynecol J 33, 2127–2132 (2022). https://doi.org/10.1007/s00192-022-05250-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-022-05250-1

Keywords

Search

Navigation